| __timestamp | Celldex Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 104381000 | 19586000 |
| Thursday, January 1, 2015 | 100171000 | 29135000 |
| Friday, January 1, 2016 | 102726000 | 42791000 |
| Sunday, January 1, 2017 | 96171000 | 49577000 |
| Monday, January 1, 2018 | 66449000 | 89209000 |
| Tuesday, January 1, 2019 | 42672000 | 69099000 |
| Wednesday, January 1, 2020 | 42534000 | 75961000 |
| Friday, January 1, 2021 | 53311000 | 90467000 |
| Saturday, January 1, 2022 | 82258000 | 74552000 |
| Sunday, January 1, 2023 | 118011000 | 91593000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Supernus Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Celldex consistently allocated a significant portion of its budget to R&D, peaking in 2023 with a 40% increase from its 2018 low. In contrast, Supernus Pharmaceuticals showed a more stable yet upward trend, with a notable 367% increase in R&D expenses from 2014 to 2023. This divergence highlights Celldex's aggressive pursuit of breakthrough therapies, while Supernus focuses on steady, sustainable growth. As the biotech landscape evolves, these investment patterns may shape the future of innovation and market leadership.
Analyzing R&D Budgets: Merck & Co., Inc. vs Celldex Therapeutics, Inc.
Research and Development Investment: Amgen Inc. vs Celldex Therapeutics, Inc.
Zoetis Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: argenx SE and Supernus Pharmaceuticals, Inc.
argenx SE or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Viatris Inc. and Celldex Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: ADMA Biologics, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: HUTCHMED (China) Limited vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and Celldex Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and MiMedx Group, Inc.